of ophi 105 117 Metab199479:542-54 nity in of initially mild or ab herapy with drugs,surgery fo 129A 33 F,Manet 。 D5A201 berg P.ansson R Wester treatm 109 ation 131 Ma naL Ma P 121 ophtha .Ban ue 110 139-1352 132 dell G 1G. W.W -193 ch JM.Pow 123 17 isk F,Tallstedt L.Abra 133B M s GE oppe nype 13 ersn .Carle A.Laurberg P. and is at 124 i G.Campi ny acti 136 t J.Or 2018 ETA Guideline for the Management 18s of Graves'Hyperthyroidism 医肺润 http://guide.medlive.cn/2018 ETA Guideline for the Management of Graves’ Hyperthyroidism Eur Thyroid J 2018;7:167–186 185 DOI: 10.1159/000490384 103 Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr: Cancer mortality following treatment for adult hyperthyroidism. Coop￾erative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998;280:347–355. 104 Bonnema SJ, Bennedbaek FN, Veje A, Marv￾ing J, Hegedus L: Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004;89: 4439–4444. 105 Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L: Resumption of methimazole after 131I therapy of hyperthy￾roid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 2003;149:485–492. 106 Bartalena L, Marcocci C, Bogazzi F, Panicuc￾ci M, Lepri A, Pinchera A: Use of corticoste￾roids to prevent progression of Graves’ oph￾thalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321: 1349–1352. 107 Jensen BE, Bonnema SJ, Hegedus L: Gluco￾corticoids do not influence the effect of ra￾dioiodine therapy in Graves’ disease. Eur J Endocrinol 2005;153:15–21. 108 Burch HB, Burman KD, Cooper DS: A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin En￾docrinol Metab 2012;97:4549–4558. 109 Bartalena L, Chiovato L, Vitti P: Manage￾ment of hyperthyroidism due to Graves’ dis￾ease: frequently asked questions and an￾swers (if any). J Endocrinol Invest 2016;39: 1105–1114. 110 Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E: What is the best de￾finitive treatment for Graves’ disease? A sys￾tematic review of the existing literature. Ann Surg Oncol 2013;20:660–667. 111 Guo Z, Yu P, Liu Z, Si Y, Jin M: Total thy￾roidectomy vs bilateral subtotal thyroidec￾tomy in patients with Graves’ diseases: a me￾ta-analysis of randomized clinical trials. Clin Endocrinol 2013;79:739–746. 112 Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R: The impor￾tance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 2008;228:320–330. 113 Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarma￾gan S, Tezelman S: Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab 2007;92:2182– 2189. 114 Edafe O, Antakia R, Laskar N, Uttley L, Bal￾asubramanian SP: Systematic review and meta-analysis of predictors of post-thyroid￾ectomy hypocalcaemia. Br J Surg 2014;101: 307–320. 115 Bartalena L, Baldeschi L, Boboridis K, Eck￾stein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves Orbitopathy: The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the man￾agement of Graves’ orbitopathy. Eur Thy￾roid J 2016;5:9–26. 116 Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F: Effects of treatment modal￾ities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endo￾crinology Consensus Statement. J Endocri￾nol Invest 2015;38:481–487. 117 Bartalena L: The dilemma of how to manage Graves’ hyperthyroidism in patients with as￾sociated orbitopathy. J Clin Endocrinol Metab 2011;96:592–599. 118 Laurberg P, Wallin G, Tallstedt L, Abraham￾Nordling M, Lundell G, Torring O: TSH-re￾ceptor autoimmunity in Graves’ disease af￾ter therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective ran￾domized study. Eur J Endocrinol 2008;158: 69–75. 119 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A: Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998;338:73–78. 120 Karlsson F, Dahlberg P, Jansson R, Wester￾mark K, Enoksson P: Importance of TSH re￾ceptor activation in the development of se￾vere endocrine ophthalmopathy. Acta En￾docrinol 1989;121(suppl 2):132–141. 121 Bartalena L, Marcocci C, Bogazzi F, Panicuc￾ci M, Lepri A, Pinchera A: Use of corticoste￾roids to prevent progression of Graves’ oph￾thalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321: 1349–1352. 122 Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A: Oc￾currence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733– 1738. 123 Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hal￾lengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G; Thyroid Study Group of TT 96: Thyroid-associated ophthalmopa￾thy after treatment for Graves’ hyper￾thyroidism with antithyroid drugs or io￾dine-131. J Clin Endocrinol Metab 2009;94: 3700–3707. 124 Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Pec￾coz P, Salvi M: Graves’ orbitopathy activa￾tion after radioactive iodine therapy with and without steroid prophylaxis. J Clin En￾docrinol Metab 2009;94:3381–3386. 125 Tallstedt L, Lundell G, Blomgren H, Bring J: Does early administration of thyroxine re￾duce the development of Graves’ ophthal￾mopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494–497. 126 Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J: A prospective study of the ef￾fects of radioiodine therapy for hyperthy￾roidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321–5323. 127 Kung AW, Yau CC, Cheng A: The incidence of ophthalmopathy after radioiodine thera￾py for Graves’ disease: prognostic factors and the role of methimazole. J Clin Endocri￾nol Metab 1994;79:542–546. 128 Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L: Lower dose prednisone prevents radioiodine-asso￾ciated exacerbation of initially mild or ab￾sent Graves’ orbitopathy: a retrospective co￾hort study. J Clin Endocrinol Metab 2010; 95:1333–1337. 129 Acharya SH, Avenell A, Philip S, Burr J, Be￾van JS, Abraham P: Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol 2008;69:943–950. 130 Shiber S, Stiebel-Kalish H, Shimon I, Gross￾man A, Robenshtok E: Glucocorticoid regi￾mens for prevention of Graves’ ophthal￾mopathy progression following radioiodine treatment: systematic review and meta-anal￾ysis. Thyroid 2014;24:1515–1523. 131 Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L: The course of Graves’ ophthalmopathy is not in￾fluenced by near total thyroidectomy: a case￾control study. Clin Endocrinol 1999;51:503– 508. 132 Marcocci C, Kahaly GJ, Krassas GE, Bartale￾na L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wi￾ersinga W; European Group on Graves Or￾bitopathy: Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011;364: 1920–1931. 133 Bartalena L, Tanda ML: Clinical practice: Graves’ ophthalmopathy. N Engl J Med 2009;360:994–1001. 134 Krassas GE, Poppe K, Glinoer D: Thyroid function and human reproductive health. Endocr Rev 2010;31:702–755. 135 Andersen SL, Olsen J, Carle A, Laurberg P: Hyperthyroidism incidence fluctuates wide￾ly in and around pregnancy and is at vari￾ance with some other autoimmune diseases: a Danish population-based study. J Clin En￾docrinol Metab 2015;100:1164–1171. 136 Laurberg P, Bournaud C, Karmisholt J, Or￾giazzi J: Management of Graves’ hyperthy￾roidism in pregnancy: focus on both mater￾nal and foetal thyroid function, and caution against surgical thyroidectomy in pregnan￾cy. Eur J Endocrinol 2009;160:1–8. http://guide.medlive.cn/